Keiretsu Capital

SpIntellx, Inc. is a computational and systems pathology company based in Pittsburgh, Pennsylvania, that specializes in spatial intelligence software products designed for analyzing pathology tissue sections in cancer diagnosis. Founded in 2017, the company offers innovative solutions such as SpIntellx, which processes image data sets from various imaging platforms and reagents, and HistoMapr, a computational guide for pathologists. Additionally, TumorMapr is utilized to analyze the spatial interactions of biomarkers within whole slide images using multiplexed fluorescence. With a focus on Precision Pathology and Spatially Intelligent Biology, SpIntellx leverages unbiased spatial analytics powered by explainable AI to enhance understanding of complex cancer biology, thereby facilitating advancements in drug development, diagnostics, and treatment strategies.

Carmell was founded in 2007 to commercialize technology developed jointly at Carnegie Mellon University and Allegheny General Hospital. The proprietary technology enables the manufacture of biologically-active plastics from blood plasma for treating injuries to bone and connective tissue. These plastics are sterile, off-the-shelf, easy to handle, shape and suture, have controlled degradation rates, contain known levels of bioactivity, and exhibit mechanical properties designed to match the repaired tissue. Carmell's plastics can be simply viewed as plastic forms of ultra-concentrated blood clots; they therefore represent the ideal biomaterials, using the body's own growth and regenerative factors to naturally promote tissue healing. The Company is focused on the sports medicine market, with products designed to accelerate healing and produce better clinical outcomes in treating injuries to connective tissue (e.g., tendons, ligaments and cartilage).

Atrin Pharmaceuticals is a biopharmaceutical company specializing in cancer treatment innovation. It focuses on developing proprietary medications, including ATRN-502 and ATRN-507, which target specific cancer cell pathways. The company's Atrize platform enables rapid identification of compounds effective against cancer cells without harming healthy ones.

Founded in 2018, Seneca Therapeutics specializes in developing oncolytic immunotherapeutics based on the Seneca Valley Virus (SVV), which selectively eliminates tumor cells. The company's focus is to create cancer therapeutics and vaccines using this virus.

Founded in 2018, Seneca Therapeutics specializes in developing oncolytic immunotherapeutics based on the Seneca Valley Virus (SVV), which selectively eliminates tumor cells. The company's focus is to create cancer therapeutics and vaccines using this virus.

Founded in 1994, PittMoss manufactures peat-free potting mixtures using recycled paper fibers. Its primary products are PittMoss and PittMoss Prime, serving commercial greenhouse growers, nurseries, and home gardeners in the United States.

Carmell was founded in 2007 to commercialize technology developed jointly at Carnegie Mellon University and Allegheny General Hospital. The proprietary technology enables the manufacture of biologically-active plastics from blood plasma for treating injuries to bone and connective tissue. These plastics are sterile, off-the-shelf, easy to handle, shape and suture, have controlled degradation rates, contain known levels of bioactivity, and exhibit mechanical properties designed to match the repaired tissue. Carmell's plastics can be simply viewed as plastic forms of ultra-concentrated blood clots; they therefore represent the ideal biomaterials, using the body's own growth and regenerative factors to naturally promote tissue healing. The Company is focused on the sports medicine market, with products designed to accelerate healing and produce better clinical outcomes in treating injuries to connective tissue (e.g., tendons, ligaments and cartilage).

Astarte Medical Partners, Inc. is a clinical intelligence company focused on enhancing health outcomes for children with medical complexities, particularly in neonatal intensive care units (NICUs). Incorporated in 2016 and based in Yardley, Pennsylvania, the company develops software that delivers a comprehensive view of clinical data in real time, specifically aimed at assessing the gut health of preterm infants. This platform allows clinical care teams to standardize and optimize feeding practices and protocol-driven care, thereby facilitating informed decision-making. Astarte Medical's suite of digital tools and predictive analytics supports nutrition and feeding practices, enabling healthcare providers to monitor growth and track clinical outcomes effectively. By improving care practices in acute settings, the company strives to make a significant impact on the long-term health of vulnerable pediatric populations.

Astarte Medical Partners, Inc. is a clinical intelligence company focused on enhancing health outcomes for children with medical complexities, particularly in neonatal intensive care units (NICUs). Incorporated in 2016 and based in Yardley, Pennsylvania, the company develops software that delivers a comprehensive view of clinical data in real time, specifically aimed at assessing the gut health of preterm infants. This platform allows clinical care teams to standardize and optimize feeding practices and protocol-driven care, thereby facilitating informed decision-making. Astarte Medical's suite of digital tools and predictive analytics supports nutrition and feeding practices, enabling healthcare providers to monitor growth and track clinical outcomes effectively. By improving care practices in acute settings, the company strives to make a significant impact on the long-term health of vulnerable pediatric populations.

Atrin Pharmaceuticals is a biopharmaceutical company specializing in cancer treatment innovation. It focuses on developing proprietary medications, including ATRN-502 and ATRN-507, which target specific cancer cell pathways. The company's Atrize platform enables rapid identification of compounds effective against cancer cells without harming healthy ones.

Founded in 1994, PittMoss manufactures peat-free potting mixtures using recycled paper fibers. Its primary products are PittMoss and PittMoss Prime, serving commercial greenhouse growers, nurseries, and home gardeners in the United States.

Indigo Biosciences, Inc. is a biosciences company based in State College, Pennsylvania, founded in 2004. The company specializes in developing products and services centered around nuclear receptors, which are key therapeutic drug targets. Its offerings include various assay kits, in vitro toxicology solutions, and custom assay development, with a focus on enhancing readability, reproducibility, and turnaround times in research. Notably, Indigo provides long-term cryopreservation of cells, facilitating convenient access to robust cell-based reporter assays. The company serves a diverse clientele, including pharmaceutical and biotechnology firms, as well as government research agencies and academic institutions, aiming to streamline the drug discovery process by reducing time, cost, and risk associated with screening small molecule compounds against functional human and non-human nuclear receptors.

Evrys Bio, LLC is a pharmaceutical company focused on developing innovative antiviral drugs that target sirtuins, proteins that play a crucial role in enhancing the body's intrinsic immune response. The company is engaged in creating broad-spectrum antiviral treatments for various infections, including respiratory syncytial virus, herpes, polyomavirus, and hepatitis viruses. Notably, Evrys Bio aims to offer a pill for treating diverse infections and a brain-penetrant antiviral for conditions like viral encephalitis. By leveraging breakthroughs from Princeton University, Evrys Bio seeks to address the challenge of acquired drug resistance and provide unique treatment options that enhance patient outcomes holistically, rather than targeting specific viruses. Established in 2012 and based in Doylestown, Pennsylvania, the company was formerly known as FORGE Life Science, LLC before rebranding in 2019.

Carmell was founded in 2007 to commercialize technology developed jointly at Carnegie Mellon University and Allegheny General Hospital. The proprietary technology enables the manufacture of biologically-active plastics from blood plasma for treating injuries to bone and connective tissue. These plastics are sterile, off-the-shelf, easy to handle, shape and suture, have controlled degradation rates, contain known levels of bioactivity, and exhibit mechanical properties designed to match the repaired tissue. Carmell's plastics can be simply viewed as plastic forms of ultra-concentrated blood clots; they therefore represent the ideal biomaterials, using the body's own growth and regenerative factors to naturally promote tissue healing. The Company is focused on the sports medicine market, with products designed to accelerate healing and produce better clinical outcomes in treating injuries to connective tissue (e.g., tendons, ligaments and cartilage).

Founded in 2009, Lungpacer Medical is a medical device company based in Vancouver, Canada. It specializes in developing therapeutic solutions to preserve and restore the strength of the diaphragm muscle in critically ill patients requiring mechanical ventilation. The company's flagship product, the Lungpacer DPT System, uses a minimally invasive, transvascular nerve stimulation approach to activate the diaphragm, potentially improving patient outcomes and reducing hospital care costs.

Founded in 2009, Lungpacer Medical is a medical device company based in Vancouver, Canada. It specializes in developing therapeutic solutions to preserve and restore the strength of the diaphragm muscle in critically ill patients requiring mechanical ventilation. The company's flagship product, the Lungpacer DPT System, uses a minimally invasive, transvascular nerve stimulation approach to activate the diaphragm, potentially improving patient outcomes and reducing hospital care costs.